Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 11/07/2025 pm IST			5-day change	1st Jan Change
438.95 ^DKK	-3.64%		-2.74%	-29.68%

07:10am	Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	RE
11/07	European stocks down with bank and healthcare drag, US-EU tariffs in focus	RE

Novo Nordisk's Obesity Drug Candidate Amycretin Delivers Up to 24% Weight Reduction

Published on 22/06/2025 at 15:26

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Clever Culture Systems says receipt of purchase order for an APAS Independence instrument from Novo Nordisk in Europe	07:10am	RE
European stocks down with bank and healthcare drag, US-EU tariffs in focus	11/07	RE
FDA May Fast Track Drug Reviews for Lower US Prices	11/07	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	11/07	MT
NOVO NORDISK : Gets a Buy rating from UBS	11/07	ZD
Wall Street Waits to Hear the Numbers	11/07
Mining, healthcare prop up European shares; US-EU trade talks in focus	10/07	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	09/07	RE
European shares close at four-week high on banks boost; US trade talks in focus	09/07	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	09/07	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	09/07	ZD
Europe rises despite new US tariff mayhem	09/07	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	08/07	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	08/07	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	08/07	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	08/07	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	08/07	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	08/07	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	08/07	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	08/07	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	08/07	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	08/07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06/08 - Q2 2025 Earnings Release

More about the company